{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:02Z","timestamp":1791644582183,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the effects of 1% azithromycin ophthalmic solution (AZM) in patients with bacterial blepharitis accompanied by meibomian gland dysfunction (MGD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study design<\/jats:title>\n                <jats:p>A multicenter, single arm, prospective interventional study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>AZM was administered to the affected eyes twice daily for the first 2 days and once daily for the subsequent 12 days. Lid margin hyperaemia\/redness, collarette at the root of the eyelashes, conjunctival hyperaemia, foreign body sensation, and epiphora were assessed on Days 1, 14, and 28. The Dry Eye-related Quality of Life Score (DEQS) and objectives related to MGD, including lid vascularity, lid margin irregularity, foaming, lid plugging, keratoconjunctival disorders, Marx line, meibum grade, and tear breakup time, were also assessed. Bacterial culture of the conjunctival sac and meibum was performed on Days 1 and 14.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-four eyes of 24 patients (10 men\/14 women, mean age 72.3\u2009\u00b1\u200913.2) were included. On Days 14 and 28, the total score, lid vascularity, lid plugging, and meibum grade showed significant improvement (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). On Day 1, 71 strains were isolated from 22 of the 24 eyes (91.7%). <jats:italic>Cutibacterium acnes<\/jats:italic>, <jats:italic>Corynebacterium<\/jats:italic> spp., and <jats:italic>Staphylococci<\/jats:italic> were detected at high frequencies. The overall disappearance rates of the bacteria in the conjunctival sac and meibum at the end of treatment were 65.7% and 58.3%, respectively. No serious ocular or systemic adverse events were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Fourteen-day treatment with AZM was effective in patients with blepharitis accompanied by MGD, and the efficacy of AZM persisted for a period after the treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10384-024-01079-x","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T06:02:21Z","timestamp":1720850541000},"page":"472-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of topical azithromycin therapy in patients with blepharitis and meibomian gland dysfunction"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-3095","authenticated-orcid":false,"given":"Jun","family":"Shimazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gakushi","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuka","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/00003226-199110010-00010","volume":"10","author":"LR Groden","year":"1991","unstructured":"Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea. 1991;10:50\u20133.","journal-title":"Cornea"},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1167\/iovs.12-9922","volume":"53","author":"SH Lee","year":"2012","unstructured":"Lee SH, Oh DH, Jung JY, Kim JC, Jeon CO. Comparative ocular microbial communities in humans with and without blepharitis. Invest Ophthalmol Vis Sci. 2012;53:5585\u201393.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/ICO.0b013e31826a04dd","volume":"31","author":"T Suzuki","year":"2012","unstructured":"Suzuki T. Meibomitis-related keratoconjunctivitis: implications and clinical significance of meibomian gland inflammation. Cornea. 2012;31:S41\u20134.","journal-title":"Cornea"},{"key":"1079_CR4","first-page":"2970","volume":"32","author":"JM Dougherty","year":"1991","unstructured":"Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1079_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10384-023-00995-8","volume":"67","author":"S Amano","year":"2023","unstructured":"Amano S, Shimazaki J, Yokoi N, Hori Y, Arita R. Committee for Meibomian Gland Dysfunction Clinical Practice Guidelines. Meibomian Gland Dysfunction Clinical Practice guidelines. Jpn J Ophthalmol. 2023;67:448\u2013539.","journal-title":"Jpn J Ophthalmol"},{"key":"1079_CR6","first-page":"486","volume":"27","author":"JM Dougherty","year":"1986","unstructured":"Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27:486\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1079_CR7","doi-asserted-by":"crossref","unstructured":"Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011; 52:1922-9.","DOI":"10.1167\/iovs.10-6997a"},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","volume":"31","author":"J Retsema","year":"1987","unstructured":"Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987;31:1939\u201347.","journal-title":"Antimicrob Agents Chemother"},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/ICO.0b013e3181ca38a0","volume":"29","author":"RM Haque","year":"2010","unstructured":"Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871\u20137.","journal-title":"Cornea"},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41433-020-0876-2","volume":"34","author":"T Tao","year":"2020","unstructured":"Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. Eye (Lond). 2020;34:1797\u2013808.","journal-title":"Eye (Lond)"},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/ICL.0000000000000729","volume":"47","author":"R Arita","year":"2021","unstructured":"Arita R, Fukuoka S. Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis. Eye Contact Lens. 2021;47:54\u20139.","journal-title":"Eye Contact Lens"},{"key":"1079_CR12","first-page":"627","volume":"27","author":"S Amano","year":"2010","unstructured":"Amano S, MGD Working Group. Definition and diagnostic criteria for meibomian gland dysfunction. J Eye. 2010;27:627\u201331. (in Japanese).","journal-title":"J Eye"},{"key":"1079_CR13","first-page":"933","volume":"123","author":"Ministry of Health","year":"2019","unstructured":"Ministry of Health. Labour and Welfare. Guideline for clinical evaluation of ophthalmologic antibiotics. Nippon Ganka Gakkai Zasshi. 2019;123:933\u201342. (in Japanese).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1079_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ajo.2016.06.025","volume":"169","author":"R Arita","year":"2016","unstructured":"Arita R, Minoura I, Morishige N, Shirakawa R, Fukuoka S, Asai K, et al. Development of definitive and reliable grading scales for meibomian gland dysfunction. Am J Ophthalmol. 2016;169:125\u201337.","journal-title":"Am J Ophthalmol"},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ajo.2005.11.004","volume":"141","author":"M Yamaguchi","year":"2006","unstructured":"Yamaguchi M, Kutsuna M, Uno T, Zheng X, Kodama T, Ohashi Y. Marx line: fluorescein staining line on the inner lid as indicator of meibomian gland function. Am J Ophthalmol. 2006;141:669\u201375.","journal-title":"Am J Ophthalmol"},{"key":"1079_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0161-6420(98)98033-2","volume":"105","author":"J Shimazaki","year":"1998","unstructured":"Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sj\u00f6gren syndrome. Ophthalmology. 1998;105:1485\u20138.","journal-title":"Ophthalmology"},{"key":"1079_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","volume":"131","author":"Y Sakane","year":"2013","unstructured":"Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-life score questionnaire. JAMA Ophthalmol. 2013;131:1331\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/OPTH.S148167","volume":"11","author":"S Amano","year":"2017","unstructured":"Amano S, Inoue K. Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction. Clin Ophthalmol. 2017;11:1677\u201382.","journal-title":"Clin Ophthalmol"},{"key":"1079_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/ICL.0000000000000535","volume":"45","author":"N Aketa","year":"2019","unstructured":"Aketa N, Shinzawa M, Kawashima M, Dogru M, Okamoto S, Tsubota K, et al. Efficacy of plate expression of Meibum on tear function and ocular surface findings in Meibomian Gland Disease. Eye Contact Lens. 2019;45:19\u201322.","journal-title":"Eye Contact Lens"},{"key":"1079_CR20","volume-title":"M100 Performance standards for Antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. M100 Performance standards for Antimicrobial susceptibility testing. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.","edition":"30"},{"key":"1079_CR21","first-page":"999","volume":"39","author":"R Nejima","year":"2022","unstructured":"Nejima R, Inoue T, Kaji Y, Suzuki T, Hattori T, Hoshi S, et al. Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis-first report: study of clinical course. J Eye. 2022;39:999\u20131004. (in Japanese).","journal-title":"J Eye"},{"key":"1079_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","volume":"25","author":"J Luchs","year":"2008","unstructured":"Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858\u201370.","journal-title":"Adv Ther"},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/ICO.0b013e3181cda38f","volume":"29","author":"GN Foulks","year":"2010","unstructured":"Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29:781\u20138.","journal-title":"Cornea"},{"key":"1079_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1590\/S0004-27492012000300006","volume":"75","author":"A Fadlallah","year":"2012","unstructured":"Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol. 2012;75:178\u201382.","journal-title":"Arq Bras Oftalmol"},{"key":"1079_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/jop.2009.0026","volume":"25","author":"EK Akpek","year":"2009","unstructured":"Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25:433\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40123-019-00205-0","volume":"8","author":"T Sakai","year":"2019","unstructured":"Sakai T, Shinno K, Kurata M, Kawamura A. Pharmacokinetics of azithromycin, levofloxacin, and ofloxacin in rabbit extraocular tissues after ophthalmic administration. Ophthalmol Ther. 2019;8:511\u20137.","journal-title":"Ophthalmol Ther"},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1001\/jamaophthalmol.2013.6030","volume":"132","author":"Y Liu","year":"2014","unstructured":"Liu Y, Kam WR, Ding J, Sullivan DA. Effect of azithromycin on lipid accumulation in immortalized human meibomian gland epithelial cells. JAMA Ophthalmol. 2014;132:226\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1079_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamaophthalmol.2015.2326","volume":"133","author":"L Zhang","year":"2015","unstructured":"Zhang L, Su Z, Zhang Z, Lin J, Li DQ, Pflugfelder SC. Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease. JAMA Ophthalmol. 2015;133:1117\u201323.","journal-title":"JAMA Ophthalmol"},{"key":"1079_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10384-022-00947-8","volume":"66","author":"R Nejima","year":"2022","unstructured":"Nejima R, Eguchi H, Todokoro D, Inoue T, Kaji Y, Suzuki T, et al. Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis: second report-bacteriological investigation. Jpn J Ophthalmol. 2022;66:579\u201389.","journal-title":"Jpn J Ophthalmol"},{"key":"1079_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jtos.2016.12.003","volume":"15","author":"SD Zhang","year":"2017","unstructured":"Zhang SD, He JN, Niu TT, Chan CY, Ren CY, Liu SS, et al. Bacteriological profile of ocular surface flora in meibomian gland dysfunction. Ocul Surf. 2017;15:242\u20137.","journal-title":"Ocul Surf"},{"key":"1079_CR31","first-page":"690","volume":"108","author":"O Terada","year":"2004","unstructured":"Terada O, Chiba K, Senoo T, Obara Y. Ocular surface temperature of meibomian gland dysfunction patients and the melting point of meibomian gland secretions. Nippon Ganka Gakkai Zasshi. 2004;108:690\u20133. (in Japanese).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1079_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1542-0124(12)70138-6","volume":"1","author":"JP McCulley","year":"2003","unstructured":"McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer. Ocul Surf. 2003;1:97\u2013106.","journal-title":"Ocul Surf"},{"key":"1079_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0924-8579(95)00009-W","volume":"5","author":"IM Hoepelman","year":"1995","unstructured":"Hoepelman IM, Schneider MM. Azithromycin: the first of the tissue-selective azalides. Int J Antimicrob Agents. 1995;5:145\u201367.","journal-title":"Int J Antimicrob Agents"},{"key":"1079_CR34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/ICO.0b013e3181cc7b1b","volume":"29","author":"R Arita","year":"2010","unstructured":"Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Tomidokoro A, et al. Proposed diagnostic criteria for seborrheic meibomian gland dysfunction. Cornea. 2010;29:980\u20134.","journal-title":"Cornea"},{"key":"1079_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1076\/ceyr.25.2.91.10159","volume":"25","author":"M Labetoulle","year":"2002","unstructured":"Labetoulle M, Frau E, Offret H, Nordmann P, Naas T. Non-preserved 1% lidocaine solution has less antibacterial properties than currently available anaesthetic eye-drops. Curr Eye Res. 2002;25:91\u20137.","journal-title":"Curr Eye Res"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-024-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-024-01079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-024-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:03:25Z","timestamp":1727125405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-024-01079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1007\/s10384-024-01079-x","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"16 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Shimazaki, None; G. Kito, Employee (Senju); M. Kamoi, None; Y. Satake, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}